| scholarly article | Q13442814 |
| P2093 | author name string | G Schuler | |
| J Y Humrich | |||
| S Greiner | |||
| L Jenne | |||
| B Sauter | |||
| P Thuman | |||
| P2860 | cites work | VIRUSES IN THE TREATMENT OF CANCER | Q61819636 |
| Viral vectors for dendritic cell-based immunotherapy | Q64377620 | ||
| Viral oncolysis | Q64378232 | ||
| Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas | Q73937540 | ||
| Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions | Q74179201 | ||
| Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial | Q78367011 | ||
| Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus | Q27483975 | ||
| Tumour-cell invasion and migration: diversity and escape mechanisms | Q29547894 | ||
| Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. | Q30305548 | ||
| Viral transport and the cytoskeleton | Q34132795 | ||
| Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study | Q34149440 | ||
| Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors | Q34169782 | ||
| Viral vectors for dendritic cell-based immunotherapy | Q34207596 | ||
| Dendritic cells resurrect antigens from dead cells. | Q34207623 | ||
| Dendritic cells as vectors for therapy | Q34339199 | ||
| Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials | Q34446288 | ||
| The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses | Q34469355 | ||
| Tumor-specific shared antigenic peptides recognized by human T cells | Q35005926 | ||
| Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases | Q35140568 | ||
| Proteolytic and non-proteolytic migration of tumour cells and leucocytes | Q35572273 | ||
| Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus | Q35842621 | ||
| Oncolytic viral therapies - the clinical experience | Q36318202 | ||
| Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. | Q36368308 | ||
| Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. | Q36370290 | ||
| Human T cell responses against melanoma | Q36427328 | ||
| Nonreplicating vaccinia vector efficiently expresses recombinant genes | Q37299518 | ||
| Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015. | Q40340116 | ||
| A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. | Q40621333 | ||
| Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule | Q40840410 | ||
| Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function | Q40850940 | ||
| Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. | Q40869541 | ||
| Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo | Q40923272 | ||
| Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha | Q41046482 | ||
| A clinical histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission | Q42445664 | ||
| Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease | Q42673382 | ||
| Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis | Q43620127 | ||
| Antigen loading of dendritic cells with whole tumor cell preparations | Q44473359 | ||
| A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models | Q44799666 | ||
| A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). | Q45529367 | ||
| Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo | Q45733521 | ||
| Immunotherapy of Malignant Melanoma With Vaccinia Virus | Q45814892 | ||
| T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas | Q60683103 | ||
| P433 | issue | 2 | |
| P921 | main subject | dendritic cell | Q506253 |
| Vaccinia virus | Q1986297 | ||
| P304 | page(s) | 344-353 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity | |
| P478 | volume | 146 |
| Q37388411 | A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity |
| Q47563356 | Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. |
| Q34956920 | Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression. |
| Q33938820 | Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells |
| Q39740447 | Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution |
| Q34465228 | Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens |
| Q26774345 | Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy |
| Q33916776 | Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals |
| Q53809292 | Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature. |
| Q24596171 | Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? |
| Q39840716 | Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication |
| Q59351803 | Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8 T cell proliferation |
| Q81574288 | Immunotherapeutic potential of oncolytic virotherapy |
| Q58110086 | Oncolytic Viruses for Canine Cancer Treatment |
| Q40907752 | Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer |
| Q37185612 | Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro |
| Q38208315 | Oncolytic virus-mediated reversal of impaired tumor antigen presentation |
| Q52309503 | Oncolytic viruses as engineering platforms for combination immunotherapy. |
| Q37300008 | Oncolytic viruses: a novel form of immunotherapy |
| Q37926486 | Oncolytic viruses: do they have a role in anti-cancer therapy? |
| Q47547580 | Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene |
| Q33826983 | Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect |
| Q51007512 | Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. |
| Q37561072 | The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon |
| Q36849770 | Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines |
| Q37239555 | Tumor infection by oncolytic reovirus primes adaptive antitumor immunity |
| Q42280873 | Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis. |
| Q39925872 | Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent |
| Q37316876 | Vaccinia virus induces programmed necrosis in ovarian cancer cells |
Search more.